Third Quarter Financial Highlights
- Total product and service revenue of
$21.5 million, 27% year-over-year growth
- Consumables revenue of
$13.7 million, including $2.5 millionof Prosigna® IVD kits, 28% year-over-year growth
- Instrument revenue of
$5.4 million, 22% year-over-year growth
- Service revenue of
$2.3 million, 33% year-over-year growth
- Collaboration revenue recognized of
$7.2 millionand cash received from collaborators of $7.3 million
“We generated strong third quarter results with instruments, consumables, and service each growing greater than 20% compared to the prior year,” stated
Recent Business Highlights
- Increased installed base to approximately 695 nCounter® Analysis Systems at September 30, 2018, representing 22% growth over the prior year
- Highlighted a record number of nCounter-related abstracts in immuno-oncology at the
Society of Immunotherapy of Cancer( SITC) annual meeting
- Launched a new panel for characterizing CAR T-Cells in basic research, as well as for quality control in manufacturing, at the
- Entered into a translational research collaboration agreement with
MacroGenics Inc.that will use NanoString’s PanCancer IO360™ Panel to explore potentially predictive biomarker signatures for MacroGenics’ checkpoint inhibitor product candidate MGD013, which is currently being studied in an open label Phase I dose escalation trial in unresectable, locally advanced or metastatic solid tumors and hematologic malignancies
GeoMx Digital Spatial Profiling (DSP) Platform
- Initiated the GeoMx Priority Site (GPS) program and commenced booking pre-orders for GeoMx Digital Spatial Profiler (DSP). Inclusion in the GPS Program will allow researchers to generate data on their samples through the GeoMx DSP Technology Access Program in advance of receiving their instrument. GPS status will be limited to the first 20 participants who purchase the commercial system.
- Announced two independent peer-reviewed studies that used the GeoMx DSP which were published in the journal, Nature Medicine. These papers highlighted the use of DSP technology to identify biomarkers correlating with response to neoadjuvant therapy in patients with high-risk melanoma.
- Received more than 100 GeoMx DSP grant program submissions from around the world. Selected the
University of Oxfordas the winning recipient of a grant for a GeoMx DSP instrument. Oxfordresearchers plan to use GeoMx DSP in a clinical trial of a novel cellular therapy, using regulatory T cells in renal transplantation, to better understand patient response and guide future decisions in their transplant medicine program.
Hyb & Seq
- Presented data demonstrating emerging applications of the Hyb & Seq™ platform for infectious disease, including rapid pathogen detection and identification as well as Antibiotic Susceptibility Testing, during the
Association for Molecular Pathologyannual meeting.
- Amended and restated our term loan facility with the
Capital Royalty Group L.P.(CRG). The amended facility permits aggregate borrowings of up to $100 million, with $60 milliondrawn at close. The proceeds of the initial draw were used to refinance NanoString’s existing CRG term loan facility, under which approximately $50 millionwas outstanding, for working capital and general corporate purposes and for transaction-related fees and expenses.
Third Quarter Financial Results
Product and service revenue for the three months ended September 30, 2018 increased by 27% to
Collaboration revenue totaled
Research and development expense increased by 46% to
Net loss for the three months ended
Outlook for 2018
The company updated its guidance for fiscal 2018 with results expected as follows:
- Product and service revenue of
$82 million to $83 million, an increase from previous guidance of $79 million to $81 million.
- Collaboration revenue of approximately
$23 million, updated from previous guidance of approximately $25 million.
- Total revenue of
$104 million to $106 million, unchanged from previous guidance.
- Gross margin on product and service revenue of 57% to 59%, unchanged from previous guidance.
- Selling, general and administrative expenses of
$77 million to $78 million, as compared to previous guidance of $76 million to $78 million.
- Research and development expenses of
$59 million to $60 million, as compared to previous guidance of $57 million to $60 million. These expenses are partially offset by approximately $20 millionof cash expected to be received from Lam Researchduring the course of 2018.
- GAAP net loss of
$70 million to $73 million, as compared to previous guidance of $68 million to $72 million.
- Net loss per share of
$2.50 to $2.60, as compared to previous guidance of $2.50 to $2.70.
Management will host a conference call today beginning at
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 2,000 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with biopharmaceutical companies to develop companion diagnostics that may be used to identify which patients are most likely to respond to a particular therapeutic treatment.
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding expectations for future revenue growth, the impact of new products and expansion into new markets, the company’s anticipated uses of amounts borrowed under its credit facilities, the growth trajectory of the company’s nCounter franchise, the anticipated launch of new platforms, the anticipated increases to the company’s liquidity, the anticipated benefits of the company’s collaboration relationships, the timing of development funding and the company’s estimated 2018 operating results. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include market acceptance of our products; delays or denials of regulatory approvals or clearances for products or applications; delays or denials of reimbursement for diagnostic products; the impact of competition; the impact of expanded sales, marketing, product development and clinical activities on operating expenses; delays or other unforeseen problems with respect to manufacturing, product development or clinical studies; adverse conditions in the general domestic and global economic markets; as well as the other risks set forth in the company's filings with the
Vice President, Investor Relations & Corporate Communications
|NANOSTRING TECHNOLOGIES, INC.|
|CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS|
|(In thousands, except per share amounts)|
|Three Months Ended
|Nine Months Ended September 30,|
|In vitro diagnostic kits||2,547||1,689||7,234||4,963|
|Total product and service revenue||21,453||16,915||59,882||50,990|
|Costs and expenses:|
|Cost of product and service revenue||9,291||7,305||25,538||22,692|
|Research and development||16,651||11,374||45,068||33,213|
|Selling, general and administrative||17,810||18,380||57,897||54,590|
|Total costs and expenses (a) (b)||43,752||37,059||128,503||110,495|
|Loss from operations||(15,136||)||(10,043||)||(51,803||)||(30,823||)|
|Other income (expense):|
|Other income, net||(46||)||(12||)||(330||)||185|
|Total other income (expense), net||(1,293||)||(1,316||)||(4,302||)||(3,851||)|
|Net loss before provision for income taxes||(16,429||)||(11,359||)||(56,105||)||(34,674||)|
|Provision for income taxes||(57||)||(45||)||(185||)||(137||)|
|Net loss per share, basic and diluted||$||(0.56||)||$||(0.45||)||$||(2.09||)||$||(1.50||)|
|Shares used in calculating basic and diluted net loss per share||29,366||25,240||26,882||23,172|
|(a) Includes $2.8 million and $3.1 million of stock-based compensation expense for the three months ended September 30, 2018 and 2017, respectively, and $8.7 million and $8.2 million for the nine months ended September 30, 2018 and 2017, respectively.|
|(b) Includes $1.0 million and $0.7 million of depreciation and amortization expense for the three months ended September 30, 2018 and 2017, respectively, and $3.0 million and $2.4 million for the nine months ended September 30, 2018 and 2017, respectively.|
|NANOSTRING TECHNOLOGIES, INC.|
|CONDENSED CONSOLIDATED BALANCE SHEETS|
|September 30,||December 31,|
|Cash and cash equivalents||$||21,199||$||26,136|
|Accounts receivable, net||18,530||19,564|
|Prepaid expenses and other||7,057||4,745|
|Total current assets||135,535||121,921|
|Property and equipment, net||15,191||14,057|
|Liabilities and Stockholders’ Equity|
|Accrued compensation and other employee benefits||9,122||8,634|
|Deferred revenue, current portion||8,905||9,229|
|Deferred rent, current portion||617||512|
|Total current liabilities||37,407||35,919|
|Deferred revenue, net of current portion||3,594||3,304|
|Deferred rent and other liabilities, net of current portion||8,143||8,499|
|Long-term debt, net of debt issuance costs||50,133||48,931|
|Total stockholders’ equity||52,085||40,109|
|Total liabilities and stockholders’ equity||$||151,362||$||136,762|
Source: NanoString Technologies, Inc.